Subcutaneous administration of a depot gonadotropin-releasing hormone agonist induces profound reproductive axis suppression in women.

Filicori M, Cognigni GE, Arnone R, Pocognoli P, Tabarelli C, Ciampaglia W, Taraborelli S, Casadio P

Fertility and sterility1 Mar 1998Cited by 13 (Europe PMC)

PMID9531874DOI10.1016/s0015-0282(97)00553-0PepBankPUB-09531874

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study13

3 results from studies that gave the peptide. 3 results from people.

01HumanNon-randomized trialPharmacokinetics
In women with benign gynecologic disorders, triptorelin remained measurable on day 196, two months after the last injection.
In plain wordsIn women with benign gynecologic disorders, triptorelin remained measurable two months after the last injection.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
Not applicableTriptorelin persistence
Study
n = 40
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
3.75 mg at 28-day intervals · intramuscular or subcutaneous · 6 monthsAs given in this study (human).
Source sentences
Summary
On day 196 (2 months after the last depot triptorelin injection), triptorelin was still measurable and gonadotropins and gonadal steroids were still suppressed.
4 context sentences(design, population, supporting numbers)
Summary · context
Prospective, controlled pharmacokinetics study.
Summary · context
Forty women with benign gynecologic disorders.
Summary · context
Triptorelin administration (3.75 mg) at 28-day intervals for 6 consecutive months.
Summary · context
Twenty patients were treated with IM triptorelin, and 20 patients were treated with SC triptorelin.
Report a problemFND-0953187410
02HumanNon-randomized trialEfficacy outcome
In women with benign gynecologic disorders, gonadotropins remained suppressed two months after the last triptorelin injection.
In plain wordsIn women with benign gynecologic disorders, gonadotropins remained suppressed two months after the last triptorelin injection.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
DecreasePersistent gonadotropin suppression
Study
n = 40
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
3.75 mg at 28-day intervals · intramuscular or subcutaneous · 6 monthsAs given in this study (human).
Source sentences
Summary
On day 196 (2 months after the last depot triptorelin injection), triptorelin was still measurable and gonadotropins and gonadal steroids were still suppressed.
4 context sentences(design, population, supporting numbers)
Summary · context
Prospective, controlled pharmacokinetics study.
Summary · context
Forty women with benign gynecologic disorders.
Summary · context
Triptorelin administration (3.75 mg) at 28-day intervals for 6 consecutive months.
Summary · context
Twenty patients were treated with IM triptorelin, and 20 patients were treated with SC triptorelin.
Report a problemFND-0953187411
03HumanNon-randomized trialEfficacy outcome
In women with benign gynecologic disorders, gonadal steroids remained suppressed two months after the last triptorelin injection.
In plain wordsIn women with benign gynecologic disorders, gonadal steroids remained suppressed two months after the last triptorelin injection.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
DecreasePersistent gonadal steroid suppression
Study
n = 40
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
3.75 mg at 28-day intervals · intramuscular or subcutaneous · 6 monthsAs given in this study (human).
Source sentences
Summary
On day 196 (2 months after the last depot triptorelin injection), triptorelin was still measurable and gonadotropins and gonadal steroids were still suppressed.
4 context sentences(design, population, supporting numbers)
Summary · context
Prospective, controlled pharmacokinetics study.
Summary · context
Forty women with benign gynecologic disorders.
Summary · context
Triptorelin administration (3.75 mg) at 28-day intervals for 6 consecutive months.
Summary · context
Twenty patients were treated with IM triptorelin, and 20 patients were treated with SC triptorelin.
Report a problemFND-0953187412

Studies that did not test the peptide alone10

In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Triptorelin (Trelstar, Decapeptyl).

04HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneNon-randomized trialSafety outcome
In women with benign gynecologic disorders, injection site redness was more frequent with subcutaneous than intramuscular triptorelin.
In plain wordsIn women with benign gynecologic disorders, injection redness was more frequent with subcutaneous than intramuscular triptorelin.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
IncreaseInjection site redness
Study
n = 40
Comparator
Intramuscular triptorelin
Outcome group
Adverse events · Skin and wound
Source sentences
Summary
The occurrence of injection site redness and itching and of some hypoestrogenic side effects was increased significantly in the SC group.
4 context sentences(design, population, supporting numbers)
Summary · context
Prospective, controlled pharmacokinetics study.
Summary · context
Forty women with benign gynecologic disorders.
Summary · context
Triptorelin administration (3.75 mg) at 28-day intervals for 6 consecutive months.
Summary · context
Twenty patients were treated with IM triptorelin, and 20 patients were treated with SC triptorelin.
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-0953187401
05HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneNon-randomized trialSafety outcome
In women with benign gynecologic disorders, injection site itching was more frequent with subcutaneous than intramuscular triptorelin.
In plain wordsIn women with benign gynecologic disorders, injection itching was more frequent with subcutaneous than intramuscular triptorelin.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
IncreaseInjection site itching
Study
n = 40
Comparator
Intramuscular triptorelin
Outcome group
Adverse events · Skin and wound
Source sentences
Summary
The occurrence of injection site redness and itching and of some hypoestrogenic side effects was increased significantly in the SC group.
4 context sentences(design, population, supporting numbers)
Summary · context
Prospective, controlled pharmacokinetics study.
Summary · context
Forty women with benign gynecologic disorders.
Summary · context
Triptorelin administration (3.75 mg) at 28-day intervals for 6 consecutive months.
Summary · context
Twenty patients were treated with IM triptorelin, and 20 patients were treated with SC triptorelin.
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-0953187402
06HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneNon-randomized trialSafety outcome
In women with benign gynecologic disorders, some hypoestrogenic side effects increased with subcutaneous compared with intramuscular triptorelin.
In plain wordsIn women with benign gynecologic disorders, some low-estrogen side effects were more frequent with subcutaneous than intramuscular triptorelin.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
IncreaseHypoestrogenic side effects
Study
n = 40
Comparator
Intramuscular triptorelin
Outcome group
Adverse events · Endocrine and hormones
Source sentences
Summary
The occurrence of injection site redness and itching and of some hypoestrogenic side effects was increased significantly in the SC group.
4 context sentences(design, population, supporting numbers)
Summary · context
Prospective, controlled pharmacokinetics study.
Summary · context
Forty women with benign gynecologic disorders.
Summary · context
Triptorelin administration (3.75 mg) at 28-day intervals for 6 consecutive months.
Summary · context
Twenty patients were treated with IM triptorelin, and 20 patients were treated with SC triptorelin.
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-0953187403
07HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneNon-randomized trialPharmacokinetics
In women with benign gynecologic disorders, plasma triptorelin was lower with subcutaneous than intramuscular administration in the first month.
In plain wordsIn women with benign gynecologic disorders, blood triptorelin was lower with subcutaneous than intramuscular administration in the first month.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
DecreasePlasma triptorelin in first month
Study
n = 40
Comparator
Intramuscular triptorelin
Outcome group
Pharmacokinetics · Pharmacology
Source sentences
Summary
Plasma triptorelin levels were significantly higher in the IM group in the first month of treatment; thereafter, the pattern reversed, with a nonsignificant trend toward higher plasma triptorelin levels in the SC group.
4 context sentences(design, population, supporting numbers)
Summary · context
Prospective, controlled pharmacokinetics study.
Summary · context
Forty women with benign gynecologic disorders.
Summary · context
Triptorelin administration (3.75 mg) at 28-day intervals for 6 consecutive months.
Summary · context
Twenty patients were treated with IM triptorelin, and 20 patients were treated with SC triptorelin.
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-0953187404
08HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneNon-randomized trialPharmacokinetics
In women with benign gynecologic disorders, later plasma triptorelin showed a nonsignificant trend higher with subcutaneous than intramuscular administration.
In plain wordsIn women with benign gynecologic disorders, later blood triptorelin tended higher with subcutaneous than intramuscular administration, without statistical significance.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
No significant changeLater plasma triptorelin
Study
n = 40
Comparator
Intramuscular triptorelin
Outcome group
Pharmacokinetics · Pharmacology
Source sentences
Summary
Plasma triptorelin levels were significantly higher in the IM group in the first month of treatment; thereafter, the pattern reversed, with a nonsignificant trend toward higher plasma triptorelin levels in the SC group.
4 context sentences(design, population, supporting numbers)
Summary · context
Prospective, controlled pharmacokinetics study.
Summary · context
Forty women with benign gynecologic disorders.
Summary · context
Triptorelin administration (3.75 mg) at 28-day intervals for 6 consecutive months.
Summary · context
Twenty patients were treated with IM triptorelin, and 20 patients were treated with SC triptorelin.
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-0953187405
09HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneNon-randomized trialEfficacy outcome
In women with benign gynecologic disorders, LH was low and did not differ between subcutaneous and intramuscular triptorelin after the first month.
In plain wordsIn women with benign gynecologic disorders, LH was low and similar with subcutaneous and intramuscular triptorelin after the first month.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
No significant changeLH after first month
Study
n = 40
Comparator
Intramuscular triptorelin
Outcome group
Sex hormones and fertility · Endocrine and hormones
Source sentences
Summary
Serum LH, FSH, estradiol, and progesterone levels were low after the first month of treatment and did not differ between the two treatment groups.
4 context sentences(design, population, supporting numbers)
Summary · context
Prospective, controlled pharmacokinetics study.
Summary · context
Forty women with benign gynecologic disorders.
Summary · context
Triptorelin administration (3.75 mg) at 28-day intervals for 6 consecutive months.
Summary · context
Twenty patients were treated with IM triptorelin, and 20 patients were treated with SC triptorelin.
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-0953187406
10HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneNon-randomized trialEfficacy outcome
In women with benign gynecologic disorders, FSH was low and did not differ between subcutaneous and intramuscular triptorelin after the first month.
In plain wordsIn women with benign gynecologic disorders, FSH was low and similar with subcutaneous and intramuscular triptorelin after the first month.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
No significant changeFSH after first month
Study
n = 40
Comparator
Intramuscular triptorelin
Outcome group
Sex hormones and fertility · Endocrine and hormones
Source sentences
Summary
Serum LH, FSH, estradiol, and progesterone levels were low after the first month of treatment and did not differ between the two treatment groups.
4 context sentences(design, population, supporting numbers)
Summary · context
Prospective, controlled pharmacokinetics study.
Summary · context
Forty women with benign gynecologic disorders.
Summary · context
Triptorelin administration (3.75 mg) at 28-day intervals for 6 consecutive months.
Summary · context
Twenty patients were treated with IM triptorelin, and 20 patients were treated with SC triptorelin.
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-0953187407
11HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneNon-randomized trialEfficacy outcome
In women with benign gynecologic disorders, estradiol was low and did not differ between subcutaneous and intramuscular triptorelin after the first month.
In plain wordsIn women with benign gynecologic disorders, estradiol was low and similar with subcutaneous and intramuscular triptorelin after the first month.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
No significant changeEstradiol after first month
Study
n = 40
Comparator
Intramuscular triptorelin
Outcome group
Sex hormones and fertility · Endocrine and hormones
Source sentences
Summary
Serum LH, FSH, estradiol, and progesterone levels were low after the first month of treatment and did not differ between the two treatment groups.
4 context sentences(design, population, supporting numbers)
Summary · context
Prospective, controlled pharmacokinetics study.
Summary · context
Forty women with benign gynecologic disorders.
Summary · context
Triptorelin administration (3.75 mg) at 28-day intervals for 6 consecutive months.
Summary · context
Twenty patients were treated with IM triptorelin, and 20 patients were treated with SC triptorelin.
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-0953187408
12HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneNon-randomized trialEfficacy outcome
In women with benign gynecologic disorders, progesterone was low and did not differ between subcutaneous and intramuscular triptorelin after the first month.
In plain wordsIn women with benign gynecologic disorders, progesterone was low and similar with subcutaneous and intramuscular triptorelin after the first month.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
No significant changeProgesterone after first month
Study
n = 40
Comparator
Intramuscular triptorelin
Outcome group
Sex hormones and fertility · Endocrine and hormones
Source sentences
Summary
Serum LH, FSH, estradiol, and progesterone levels were low after the first month of treatment and did not differ between the two treatment groups.
4 context sentences(design, population, supporting numbers)
Summary · context
Prospective, controlled pharmacokinetics study.
Summary · context
Forty women with benign gynecologic disorders.
Summary · context
Triptorelin administration (3.75 mg) at 28-day intervals for 6 consecutive months.
Summary · context
Twenty patients were treated with IM triptorelin, and 20 patients were treated with SC triptorelin.
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-0953187409
13HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneNon-randomized trialEfficacy outcome
In women with benign gynecologic disorders, spontaneous menses returned later with subcutaneous than intramuscular triptorelin.
In plain wordsIn women with benign gynecologic disorders, menstruation returned later with subcutaneous than intramuscular triptorelin.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
IncreaseTime to spontaneous menses
Study
n = 40
Comparator
Intramuscular triptorelin
Outcome group
Sex hormones and fertility · Endocrine and hormones
Source sentences
Summary
Spontaneous menses returned significantly later in the SC group than in the IM group.
4 context sentences(design, population, supporting numbers)
Summary · context
Prospective, controlled pharmacokinetics study.
Summary · context
Forty women with benign gynecologic disorders.
Summary · context
Triptorelin administration (3.75 mg) at 28-day intervals for 6 consecutive months.
Summary · context
Twenty patients were treated with IM triptorelin, and 20 patients were treated with SC triptorelin.
In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).
Report a problemFND-0953187413

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.